Cargando…

Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay

BACKGROUND: Adaptive immune responses to structural proteins of the virion play a crucial role in protection against coronavirus disease 2019 (COVID-19). We therefore studied T cell responses against multiple SARS-CoV-2 structural proteins in a large cohort using a simple, fast, and high-throughput...

Descripción completa

Detalles Bibliográficos
Autores principales: Brand, Isabel, Gilberg, Leonard, Bruger, Jan, Garí, Mercè, Wieser, Andreas, Eser, Tabea M., Frese, Jonathan, Ahmed, Mohamed I. M., Rubio-Acero, Raquel, Guggenbuehl Noller, Jessica M., Castelletti, Noemi, Diekmannshemke, Jana, Thiesbrummel, Sophie, Huynh, Duc, Winter, Simon, Kroidl, Inge, Fuchs, Christiane, Hoelscher, Michael, Roider, Julia, Kobold, Sebastian, Pritsch, Michael, Geldmacher, Christof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173205/
https://www.ncbi.nlm.nih.gov/pubmed/34093595
http://dx.doi.org/10.3389/fimmu.2021.688436
_version_ 1783702678837133312
author Brand, Isabel
Gilberg, Leonard
Bruger, Jan
Garí, Mercè
Wieser, Andreas
Eser, Tabea M.
Frese, Jonathan
Ahmed, Mohamed I. M.
Rubio-Acero, Raquel
Guggenbuehl Noller, Jessica M.
Castelletti, Noemi
Diekmannshemke, Jana
Thiesbrummel, Sophie
Huynh, Duc
Winter, Simon
Kroidl, Inge
Fuchs, Christiane
Hoelscher, Michael
Roider, Julia
Kobold, Sebastian
Pritsch, Michael
Geldmacher, Christof
author_facet Brand, Isabel
Gilberg, Leonard
Bruger, Jan
Garí, Mercè
Wieser, Andreas
Eser, Tabea M.
Frese, Jonathan
Ahmed, Mohamed I. M.
Rubio-Acero, Raquel
Guggenbuehl Noller, Jessica M.
Castelletti, Noemi
Diekmannshemke, Jana
Thiesbrummel, Sophie
Huynh, Duc
Winter, Simon
Kroidl, Inge
Fuchs, Christiane
Hoelscher, Michael
Roider, Julia
Kobold, Sebastian
Pritsch, Michael
Geldmacher, Christof
author_sort Brand, Isabel
collection PubMed
description BACKGROUND: Adaptive immune responses to structural proteins of the virion play a crucial role in protection against coronavirus disease 2019 (COVID-19). We therefore studied T cell responses against multiple SARS-CoV-2 structural proteins in a large cohort using a simple, fast, and high-throughput approach. METHODS: An automated interferon gamma release assay (IGRA) for the Nucleocapsid (NC)-, Membrane (M)-, Spike-C-terminus (SCT)-, and N-terminus-protein (SNT)-specific T cell responses was performed using fresh whole blood from study subjects with convalescent, confirmed COVID-19 (n = 177, more than 200 days post infection), exposed household members (n = 145), and unexposed controls (n = 85). SARS-CoV-2-specific antibodies were assessed using Elecsys(®) Anti-SARS-CoV-2 (Ro-N-Ig) and Anti-SARS-CoV-2-ELISA (IgG) (EI-S1-IgG). RESULTS: 156 of 177 (88%) previously PCR confirmed cases were still positive by Ro-N-Ig more than 200 days after infection. In T cells, most frequently the M-protein was targeted by 88% seropositive, PCR confirmed cases, followed by SCT (85%), NC (82%), and SNT (73%), whereas each of these antigens was recognized by less than 14% of non-exposed control subjects. Broad targeting of these structural virion proteins was characteristic of convalescent SARS-CoV-2 infection; 68% of all seropositive individuals targeted all four tested antigens. Indeed, anti-NC antibody titer correlated loosely, but significantly with the magnitude and breadth of the SARS-CoV-2-specific T cell response. Age, sex, and body mass index were comparable between the different groups. CONCLUSION: SARS-CoV-2 seropositivity correlates with broad T cell reactivity of the structural virus proteins at 200 days after infection and beyond. The SARS-CoV-2-IGRA can facilitate large scale determination of SARS-CoV-2-specific T cell responses with high accuracy against multiple targets.
format Online
Article
Text
id pubmed-8173205
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81732052021-06-04 Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay Brand, Isabel Gilberg, Leonard Bruger, Jan Garí, Mercè Wieser, Andreas Eser, Tabea M. Frese, Jonathan Ahmed, Mohamed I. M. Rubio-Acero, Raquel Guggenbuehl Noller, Jessica M. Castelletti, Noemi Diekmannshemke, Jana Thiesbrummel, Sophie Huynh, Duc Winter, Simon Kroidl, Inge Fuchs, Christiane Hoelscher, Michael Roider, Julia Kobold, Sebastian Pritsch, Michael Geldmacher, Christof Front Immunol Immunology BACKGROUND: Adaptive immune responses to structural proteins of the virion play a crucial role in protection against coronavirus disease 2019 (COVID-19). We therefore studied T cell responses against multiple SARS-CoV-2 structural proteins in a large cohort using a simple, fast, and high-throughput approach. METHODS: An automated interferon gamma release assay (IGRA) for the Nucleocapsid (NC)-, Membrane (M)-, Spike-C-terminus (SCT)-, and N-terminus-protein (SNT)-specific T cell responses was performed using fresh whole blood from study subjects with convalescent, confirmed COVID-19 (n = 177, more than 200 days post infection), exposed household members (n = 145), and unexposed controls (n = 85). SARS-CoV-2-specific antibodies were assessed using Elecsys(®) Anti-SARS-CoV-2 (Ro-N-Ig) and Anti-SARS-CoV-2-ELISA (IgG) (EI-S1-IgG). RESULTS: 156 of 177 (88%) previously PCR confirmed cases were still positive by Ro-N-Ig more than 200 days after infection. In T cells, most frequently the M-protein was targeted by 88% seropositive, PCR confirmed cases, followed by SCT (85%), NC (82%), and SNT (73%), whereas each of these antigens was recognized by less than 14% of non-exposed control subjects. Broad targeting of these structural virion proteins was characteristic of convalescent SARS-CoV-2 infection; 68% of all seropositive individuals targeted all four tested antigens. Indeed, anti-NC antibody titer correlated loosely, but significantly with the magnitude and breadth of the SARS-CoV-2-specific T cell response. Age, sex, and body mass index were comparable between the different groups. CONCLUSION: SARS-CoV-2 seropositivity correlates with broad T cell reactivity of the structural virus proteins at 200 days after infection and beyond. The SARS-CoV-2-IGRA can facilitate large scale determination of SARS-CoV-2-specific T cell responses with high accuracy against multiple targets. Frontiers Media S.A. 2021-05-20 /pmc/articles/PMC8173205/ /pubmed/34093595 http://dx.doi.org/10.3389/fimmu.2021.688436 Text en Copyright © 2021 Brand, Gilberg, Bruger, Garí, Wieser, Eser, Frese, Ahmed, Rubio-Acero, Guggenbuehl Noller, Castelletti, Diekmannshemke, Thiesbrummel, Huynh, Winter, Kroidl, Fuchs, Hoelscher, Roider, Kobold, Pritsch and Geldmacher https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Brand, Isabel
Gilberg, Leonard
Bruger, Jan
Garí, Mercè
Wieser, Andreas
Eser, Tabea M.
Frese, Jonathan
Ahmed, Mohamed I. M.
Rubio-Acero, Raquel
Guggenbuehl Noller, Jessica M.
Castelletti, Noemi
Diekmannshemke, Jana
Thiesbrummel, Sophie
Huynh, Duc
Winter, Simon
Kroidl, Inge
Fuchs, Christiane
Hoelscher, Michael
Roider, Julia
Kobold, Sebastian
Pritsch, Michael
Geldmacher, Christof
Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
title Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
title_full Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
title_fullStr Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
title_full_unstemmed Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
title_short Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
title_sort broad t cell targeting of structural proteins after sars-cov-2 infection: high throughput assessment of t cell reactivity using an automated interferon gamma release assay
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173205/
https://www.ncbi.nlm.nih.gov/pubmed/34093595
http://dx.doi.org/10.3389/fimmu.2021.688436
work_keys_str_mv AT brandisabel broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT gilbergleonard broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT brugerjan broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT garimerce broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT wieserandreas broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT esertabeam broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT fresejonathan broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT ahmedmohamedim broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT rubioaceroraquel broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT guggenbuehlnollerjessicam broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT castellettinoemi broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT diekmannshemkejana broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT thiesbrummelsophie broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT huynhduc broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT wintersimon broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT kroidlinge broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT fuchschristiane broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT hoelschermichael broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT roiderjulia broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT koboldsebastian broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT pritschmichael broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay
AT geldmacherchristof broadtcelltargetingofstructuralproteinsaftersarscov2infectionhighthroughputassessmentoftcellreactivityusinganautomatedinterferongammareleaseassay